Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review

被引:21
作者
El-Nakeep, Sarah [1 ]
Rashad, Noha [2 ]
Oweira, Hani [3 ,4 ]
Schmidt, Jan [4 ]
Helbling, Daniel [5 ]
Giryes, Anwar [3 ]
Petrausch, Ulf [5 ]
Mehrabi, Arianeb [4 ]
Decker, Michael [3 ]
Abdel-Rahman, Omar [3 ,6 ]
机构
[1] Ain Shams Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Fac Med, Cairo, Egypt
[2] Maadi Mil Hosp, Dept Med Oncol, Cairo, Egypt
[3] Swiss Canc Inst, Dept Surg, Zurich, Switzerland
[4] Heidelberg Univ, Dept Gen Visceral & Transplant Surg, Heidelberg, Germany
[5] Gastrointestinal Tumor Ctr Zurich GITZ, Dept Surg, OncoCtr Zurich, Zurich, Switzerland
[6] Ain Shams Univ, Dept Clin Oncol, Fac Med, Cairo, Egypt
关键词
HIPEC; hepatic resection; cytoreduction; colorectal cancer; peritoneal carcinomatosis; combined modality; HIGH-RISK; CARCINOMATOSIS; CANCER; MANAGEMENT; ORIGIN; HIPEC; DISSEMINATION; BEVACIZUMAB; RESECTION; DISEASE;
D O I
10.1080/17474124.2017.1284586
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: We aimed to assess the efficacy and safety of delivering intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases.Areas covered: A comprehensive literature search using PubMed was conducted to screen for eligible records. Studies evaluating colorectal surgery and intraperitoneal chemotherapy combined with curative treatment of liver metastases were included. We excluded duplicate publications. Sixty-seven full-text papers were assessed and six papers were finally included. The overall survival in the included studies ranged from 6-49months. Five-year survival ranged from 18%-28%, three-year survival ranged from 22%-42% and two-year survival ranged from 34%-78%. Survival was lower in patients with liver metastases and peritoneal carcinomatosis (PC) than those with PC alone in the majority of studies.Expert commentary: This review poses questions rather than presenting answers. The heterogeneity of survival data suggests the possible benefit of this aggressive treatment approach in selected patients. Standardization of the technique used for intraperitoneal chemotherapy instillation, agent used as well as the systemic chemotherapy and targeted therapy type and duration through prospective controlled trials is required to provide an evidence of a higher strength to support or prohibit this treatment strategy.
引用
收藏
页码:249 / 258
页数:10
相关论文
共 51 条
  • [31] Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes
    Hadden, William J.
    de Reuver, Philip R.
    Brown, Kai
    Mittal, Anubhav
    Samra, Jaswinder S.
    Hugh, Thomas J.
    [J]. HPB, 2016, 18 (03) : 209 - 220
  • [32] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Link, Hartmut
    Niederle, Norbert
    Rost, Andreas
    Hoeffkes, Heinz-Gert
    Moehler, Markus
    Lindig, Reinhard U.
    Modest, Dominik P.
    Rossius, Lisa
    Kirchner, Thomas
    Jung, Andreas
    Stintzing, Sebastian
    [J]. LANCET ONCOLOGY, 2014, 15 (10) : 1065 - 1075
  • [33] The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study
    Hompes, D.
    D'Hoore, A.
    Wolthuis, A.
    Fieuws, S.
    Mirck, B.
    Bruin, S.
    Verwaal, V.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (06) : 527 - 532
  • [34] Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review
    Honore, Charles
    Goere, Diane
    Souadka, Amine
    Dumont, Frederic
    Elias, Dominique
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (01) : 183 - 192
  • [35] Huang CQ, 2014, PLOS ONE, P93
  • [36] Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival
    Kakar, S
    Aksoy, S
    Burgart, LJ
    Smyrk, TC
    [J]. MODERN PATHOLOGY, 2004, 17 (06) : 696 - 700
  • [37] Kheirelseid E., 2013, American Journal of Molecular Biology, V3, P72, DOI DOI 10.4236/AJMB.2013.32010
  • [38] Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver Metastases
    Kianmanesh, Reza
    Scaringi, Stefano
    Sabate, Jean-Marc
    Castel, Benjamin
    Pons-Kerjean, Nathalie
    Coffin, Benoit
    Hay, Jean-Marie
    Flamant, Yves
    Msika, Simon
    [J]. ANNALS OF SURGERY, 2007, 245 (04) : 597 - 603
  • [39] Treatment of peritoneal metastases from colorectal cancer
    Maerz, Loreen
    Piso, Pompiliu
    [J]. GASTROENTEROLOGY REPORT, 2015, 3 (04): : 298 - 302
  • [40] Should Patients With Peritoneal Carcinomatosis of Colorectal Origin With Synchronous Liver Metastases Be Treated With a Curative Intent? A Case-Control Study
    Maggiori, Leon
    Goere, Diane
    Viana, Benjamin
    Tzanis, Dimitrios
    Dumont, Frederic
    Honore, Charles
    Eveno, Clarisse
    Elias, Dominique
    [J]. ANNALS OF SURGERY, 2013, 258 (01) : 116 - 121